US President Trump said on the 16th that the prices of popular diabetes and weight loss drugs in the United States, including Novo Nordisk, a drug produced by Novo Nordisk of Denmark, will drop sharply, which has triggered a shock in the market pharmaceutical sector. On the 17th, the price of the Norwegian stock on the Copenhagen exchange fell sharply.

Trump said at the White House on the 16th that The U.S. price of Novo Nordisk manufactured by Denmark's Novo Nordisk will "soon drop significantly", the monthly out-of-pocket fee for patients using Novotec will be reduced to US$150 (approximately RMB 1070), while the current price of Novotec in the United States is approximately US$1000 (approximately RMB 7125) per month. However, the head of the Federal Centers for Medicare and Medicaid Services later clarified that negotiations on prices for such drugs were still ongoing and no agreement had been reached. A Novo Nordisk spokesperson also said on the same day that the company was in discussions with the Trump administration.

Affected by Trump's price cut remarks, on the 17th, Novo Nordisk's share price fell more than 6.3% in Copenhagen, DenmarkNorwegian Pharmaceuticals, the main competitor of Norwegian Pharmaceuticals Denmark, fell more than 8% and the stock price of Norwegian Pharmaceuticals in the United States fell 2% in New York. It is understood that Norwegian Pharmaceuticals, the main active ingredient of Norwegian Pharmaceuticals, has been approved in many countries for the treatment of diabetes and weight loss, and the global scale of related markets reaches tens of billions of dollars annually. In addition to Norwegian Pharmaceuticals and Norwegian Pharmaceuticals, pharmaceutical companies such as Norwegian Pharmaceuticals and Norwegian Pharmaceuticals have also launched similar drugs in recent years.

Source: CCTV Finance